Health brief
Liquid Biopsies and Rapid-Response Vaccines
FDA approves a new blood test for colorectal cancer as Oxford researchers fast-track an Ebola vaccine in human trials.
Health
Blood tests are lowering the friction for cancer screening — providing a convenient tool to increase compliance, though they cannot yet replace diagnostic colonoscopies.
BackgroundColorectal cancer is the second leading cause of cancer deaths in the US, yet compliance with invasive screening methods remains low. Blood-based liquid biopsies offer a more convenient option, though they are traditionally less effective at detecting precancerous growths than colonoscopies.
- The test demonstrated 81.1% sensitivity for detecting colorectal cancer in a massive 48,000-subject trial, establishing a robust clinical baseline for noninvasive blood-based screening.
- The test detected only 13.7% of advanced precancerous lesions, which could lead some high-risk patients to bypass critical early preventive interventions.
- The regulatory milestone triggers a $100M payment from commercial partner Abbott Laboratories, boosting Freenome's balance sheet ahead of the nationwide commercial launch this fall.
Health
Scientists are racing to deploy an unproven vaccine to stop an Ebola outbreak — a high-risk manufacturing play designed to bypass traditional regulatory timelines.
BackgroundThe Bundibugyo strain of Ebola is a highly lethal species that currently lacks any approved vaccine or targeted therapeutic. This experimental candidate leverages the same viral vector technology that Oxford researchers previously used to develop AstraZeneca's COVID-19 vaccine.
- Researchers developed the experimental vaccine in just 8 weeks, marking a dramatic acceleration of traditional vaccine development timelines to address the growing crisis.
- The Serum Institute of India has already manufactured 620,000 doses, allowing for immediate regional distribution if the initial safety trial is successful.
- The trial will evaluate safety and immune response in 50 healthy adults before initiating wider field trials in the Democratic Republic of the Congo.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.